Atomwise announced the launch of a 10 billion compound AI-powered virtual drug screening initiative for pediatric oncology, in collaboration with Enamine Ltd., the world’s largest chemical supplier. The goal of this initiative – called the 10-to-the-10 program – is to dramatically increase the discovery of safer small molecules to treat pediatric cancers. When completed, it will stand as the largest ever virtual drug screen. 10-to-the-10 Program OverviewCancer is diagnosed in more than 15,000
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Sanofi and Google to Establish Virtual Healthcare Innovation Lab Focused on AI-Enabled Datasets
French pharmaceutical company Sanofi and Google today announced its plan to establish a new virtual Innovation Lab that will leverage emerging data technologies to spur the transformation of healthcare delivery. The partnership will change how Sanofi develops new treatments and will focus on three key objectives1. Better understand patients and diseases,2. Incease Sanofi’s operational efficiency3. Improve the experience of Sanofi’s patients and customersVirtual Innovation Lab
Read More
Dassault Systèmes Acquires Clinical Trial Platform Medidata for $5.8B
French technology giant Dassault Systèmes has agreed to acquire Medidata, a life sciences digital transformation company in an all-cash deal for $92.25 per share valued at $5.8 billion. With the acquisition of Medidata and its clinical and commercial solutions, Dassault Systèmes plans to increase market penetration into the Life Sciences industry with an integrated business experience platform for an end-to-end approach to research and discovery, development, clinical testing, manufacturing and
Read More
Clinical Operations Makes Highest Use of Artificial Intelligence, Tufts Study Finds
Clinical operations function makes the highest use of artificial intelligence (AI) (61%), followed by pharmacovigilance/safety/risk management (57%), and information technology (IT) (55%), according to an analysis recently completed by the Tufts Center for the Study of Drug Development. The analysis, summarized in the May/June Tufts CSDD Impact Report, reveals the pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk
Read More
RefleXion Medical Receives $60M Loan for Biology Guiding Radiotherapy Machine
RefleXion Medical, Inc., a biotargeting oncology company developing the first and only biology-guided radiotherapy (BgRT) machine* for targeted cancer treatment has received a $60M senior secured term loan from Oxford Finance LLC. The company plans to use the loan to support the completion of the FDA clearance process for its biology-guided BgRT system and its subsequent commercial launch. Building from Positron
Emission Tomography Positron emission tomography (PET) is an established
Read More
Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the collaboration, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.Generates Insights from Real-World Evidence for Potential Use in Regulatory FilingsThis effort will identify existing patients within
Read More
7 Trends Accelerating “TechBio” – The Life Sciences and Computer Sciences Convergence
We are now living in what I’m calling the
TechBio revolution. That’s not a typo that should read BioTech, but rather a
new way of looking at the convergence of technology and biology. TechBio is defined as an engineering-first approach of biological processes for industrial, and other purposes, especially the genetic manipulation of microorganisms for the production of antibiotics, hormones, and so on. A process that uses AI and data-enabled discovery to complement the exploration of
Read More
Accenture: How New Science is Reshaping The Biopharma Landscape
Accenture has released new research that unveils strong evidence that the biopharma industry is facing compressive disruption when a series of innovations, macroeconomic factors, and other changes combine to squeeze profits over a decade or more. However, it also unveils a powerful growth engine: an emerging category that Accenture calls 'New Science' that is expected to drive 54% of the biopharma industry’s growth through 2022. What is New Science? New Science is an evolving, unique
Read More
